Mediwound announces concurrent registered direct and private placement offerings priced at-the-market of approximately $30 million

Yavne, israel, sept. 22, 2022 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (the “company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement with several institutional and accredited investors (the “registered direct securities purchase agreement”) for the sale and purchase of 7,575,513 shares of the company's ordinary shares, par value nis 0.01 (the “ordinary shares”), at a purchase price of $1.75 per share, in a registered direct offering (the “registered direct offering”). additionally pursuant to the registered direct securities purchase agreement, the company has also agreed to issue to these investors unregistered warrants (the “warrants”) to purchase up to 7,575,513 ordinary shares in a concurrent private placement. the warrants will have an exercise price of $1.925 per ordinary share and will become exercisable upon the company's receipt of shareholder approval to increase the number of its authorized ordinary shares, pursuant to the company's amended and restated articles of association, and will expire four years thereafter. the gross proceeds of the registered direct offering are expected to be approximately $13.26 million. the company expects the registered direct offering to close on or about september 26, 2022, subject to the satisfaction of customary closing conditions.
MDWD Ratings Summary
MDWD Quant Ranking